Ind-Swift Laboratories Limited (INDSWFTLAB.NS)
INR 83.83
(1.35%)
INR 83.83
(1.35%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 4.2 Billion INR | 784.44% |
| 2022 | 475.96 Million INR | 2314.83% |
| 2021 | -21.49 Million INR | 31.72% |
| 2020 | -31.47 Million INR | 85.15% |
| 2019 | -211.88 Million INR | -155.12% |
| 2018 | 384.4 Million INR | 75.37% |
| 2017 | 219.19 Million INR | 155.97% |
| 2016 | -391.6 Million INR | 33.27% |
| 2015 | -586.87 Million INR | 50.83% |
| 2014 | -1.19 Billion INR | 2.17% |
| 2013 | -1.22 Billion INR | -3.43% |
| 2012 | -1.17 Billion INR | -232.31% |
| 2011 | 891.6 Million INR | -0.34% |
| 2010 | 894.62 Million INR | 58.66% |
| 2009 | 563.86 Million INR | 39.6% |
| 2008 | 403.91 Million INR | 28.55% |
| 2007 | 314.21 Million INR | 72.28% |
| 2006 | 182.38 Million INR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 9.35 Million INR | -99.61% |
| 2023 Q2 | 316.56 Million INR | 83.6% |
| 2023 Q1 | 172.42 Million INR | 168.63% |
| 2023 FY | 4.2 Billion INR | 784.44% |
| 2023 Q4 | 2.38 Billion INR | 1129.85% |
| 2023 Q3 | 194.18 Million INR | -38.66% |
| 2022 Q3 | 274.97 Million INR | 8.5% |
| 2022 Q1 | 198.78 Million INR | 132.35% |
| 2022 FY | 475.96 Million INR | 2314.83% |
| 2022 Q4 | -251.23 Million INR | -191.37% |
| 2022 Q2 | 253.43 Million INR | 27.49% |
| 2021 Q2 | 244.7 Million INR | 30.13% |
| 2021 FY | -21.49 Million INR | 31.72% |
| 2021 Q1 | 188.04 Million INR | 163.47% |
| 2021 Q3 | 160.29 Million INR | -34.49% |
| 2021 Q4 | -614.53 Million INR | -483.38% |
| 2020 Q1 | 45.72 Million INR | -70.77% |
| 2020 FY | -31.47 Million INR | 85.15% |
| 2020 Q4 | -296.25 Million INR | -356.54% |
| 2020 Q3 | 115.48 Million INR | 16.39% |
| 2020 Q2 | 99.22 Million INR | 117.01% |
| 2019 Q3 | -90.25 Million INR | 35.33% |
| 2019 FY | -211.88 Million INR | -155.12% |
| 2019 Q1 | -138.47 Million INR | 62.16% |
| 2019 Q2 | -139.57 Million INR | -0.79% |
| 2019 Q4 | 156.42 Million INR | 273.31% |
| 2018 Q3 | 402.92 Million INR | 1111.33% |
| 2018 FY | 384.4 Million INR | 75.37% |
| 2018 Q4 | -365.93 Million INR | -190.82% |
| 2018 Q2 | 33.26 Million INR | -88.18% |
| 2018 Q1 | 281.34 Million INR | 0.0% |
| 2017 FY | 219.19 Million INR | 155.97% |
| 2016 FY | -391.6 Million INR | 33.27% |
| 2015 FY | -586.87 Million INR | 50.83% |
| 2014 FY | -1.19 Billion INR | 2.17% |
| 2013 FY | -1.22 Billion INR | -3.43% |
| 2012 Q4 | -232.32 Million INR | -93.14% |
| 2012 Q3 | -120.28 Million INR | 69.45% |
| 2012 Q1 | -433.26 Million INR | 0.0% |
| 2012 Q2 | -393.77 Million INR | 9.11% |
| 2012 FY | -1.17 Billion INR | -232.31% |
| 2011 FY | 891.6 Million INR | -0.34% |
| 2010 FY | 894.62 Million INR | 58.66% |
| 2009 FY | 563.86 Million INR | 39.6% |
| 2008 FY | 403.91 Million INR | 28.55% |
| 2007 FY | 314.21 Million INR | 72.28% |
| 2006 FY | 182.38 Million INR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 6.15 Billion INR | 31.642% |
| Hester Biosciences Limited | 188.89 Million INR | -2128.607% |
| Aarti Drugs Limited | 1.71 Billion INR | -145.576% |
| Aarti Pharmalabs Limited | 2.16 Billion INR | -94.079% |
| Albert David Limited | 754.2 Million INR | -458.156% |
| Alembic Limited | 2.68 Billion INR | -56.713% |
| Alkem Laboratories Limited | 17.95 Billion INR | 76.558% |
| Bafna Pharmaceuticals Limited | 73.47 Million INR | -5629.006% |
| Bajaj HealthCare Limited | -837.93 Million INR | 602.382% |
| Biofil Chemicals and Pharmaceuticals Limited | 7.09 Million INR | -59257.248% |
| Brooks Laboratories Limited | -195.91 Million INR | 2248.651% |
| Eris Lifesciences Limited | 3.91 Billion INR | -7.393% |
| FDC Limited | 3.05 Billion INR | -37.919% |
| Glenmark Life Sciences Limited | 4.7 Billion INR | 10.603% |
| Gufic Biosciences Limited | 861.35 Million INR | -388.72% |
| Hikal Limited | 696 Million INR | -504.83% |
| Ind-Swift Limited | 142.31 Million INR | -2857.998% |
| Innova Captab Limited | 943.45 Million INR | -346.194% |
| IOL Chemicals and Pharmaceuticals Limited | 1.34 Billion INR | -213.146% |
| Jagsonpal Pharmaceuticals Limited | 224.63 Million INR | -1774.022% |
| Jubilant Pharmova Limited | 771 Million INR | -445.994% |
| Lincoln Pharmaceuticals Limited | 933.04 Million INR | -351.168% |
| Lupin Limited | 19.14 Billion INR | 78.012% |
| Mangalam Drugs & Organics Limited | -90.71 Million INR | 4740.383% |
| Medico Remedies Limited | 82.9 Million INR | -4977.393% |
| Morepen Laboratories Limited | 961.59 Million INR | -337.773% |
| Nectar Lifesciences Limited | 49.95 Million INR | -8327.66% |
| Orchid Pharma Limited | 921.66 Million INR | -356.74% |
| Procter & Gamble Health Limited | 2 Billion INR | -109.454% |
| RPG Life Sciences Limited | 876.6 Million INR | -380.221% |
| Kilitch Drugs (India) Limited | 146.01 Million INR | -2783.022% |
| Sigachi Industries Limited | 571.8 Million INR | -636.202% |
| Solara Active Pharma Sciences Limited | -5.67 Billion INR | 174.193% |
| Suven Pharmaceuticals Limited | 3 Billion INR | -40.189% |
| Themis Medicare Limited | 435.23 Million INR | -867.199% |
| Unichem Laboratories Limited | -704.74 Million INR | 697.326% |
| Vaishali Pharma Limited | 7.18 Million INR | -58456.35% |
| Wanbury Limited | 559.56 Million INR | -652.304% |
| Windlas Biotech Limited | 581.87 Million INR | -623.463% |
| ZIM Laboratories Limited | 172.46 Million INR | -2340.866% |
| Ipca Laboratories Limited | 5.47 Billion INR | 23.091% |
| Sun Pharmaceutical Industries Limited | 95.76 Billion INR | 95.604% |
| Venus Remedies Limited | 284.9 Million INR | -1377.535% |
| Sakar Healthcare Limited | 116.7 Million INR | -3506.933% |
| Aurobindo Pharma Limited | 31.72 Billion INR | 86.733% |
| Divi's Laboratories Limited | 16 Billion INR | 73.69% |
| AstraZeneca Pharma India Limited | 1.61 Billion INR | -160.641% |
| Mankind Pharma Limited | 19.12 Billion INR | 77.994% |
| Sequent Scientific Limited | -358.69 Million INR | 1273.608% |
| Laurus Labs Limited | 1.6 Billion INR | -162.2% |
| Neuland Laboratories Limited | 3 Billion INR | -40.284% |
| J. B. Chemicals & Pharmaceuticals Limited | 5.52 Billion INR | 23.825% |
| Glenmark Pharmaceuticals Limited | -15.01 Billion INR | 128.033% |
| Zydus Lifesciences Limited | 38.59 Billion INR | 89.093% |
| Amrutanjan Health Care Limited | 449.72 Million INR | -836.04% |
| Wockhardt Limited | -4.63 Billion INR | 190.92% |
| Bal Pharma Limited | 73.92 Million INR | -5594.673% |
| Dr. Reddy's Laboratories Limited | 55.68 Billion INR | 92.44% |
| Bliss GVS Pharma Limited | 754.54 Million INR | -457.904% |
| Par Drugs and Chemicals Limited | 145.01 Million INR | -2802.983% |
| Caplin Point Laboratories Limited | 4.57 Billion INR | 7.904% |
| Shilpa Medicare Limited | 318.74 Million INR | -1220.697% |
| Valiant Laboratories Limited | 3.19 Million INR | -131615.144% |
| Ajanta Pharma Limited | 8.16 Billion INR | 48.422% |
| Aarey Drugs & Pharmaceuticals Limited | 46.83 Million INR | -8887.863% |
| Granules India Limited | 4.05 Billion INR | -3.862% |
| Medicamen Biotech Limited | 109.31 Million INR | -3751.08% |
| Syncom Formulations (India) Limited | 253.14 Million INR | -1562.946% |
| Piramal Enterprises Limited | -16.83 Billion INR | 125.005% |
| Torrent Pharmaceuticals Limited | 16.56 Billion INR | 74.585% |
| NATCO Pharma Limited | 13.88 Billion INR | 69.678% |
| Suven Life Sciences Limited | -1.05 Billion INR | 500.625% |
| Krebs Biochemicals & Industries Limited | -197.28 Million INR | 2233.785% |
| Strides Pharma Science Limited | -706.14 Million INR | 696.145% |
| Indoco Remedies Limited | 984.6 Million INR | -327.545% |
| Alpa Laboratories Limited | 167.76 Million INR | -2409.234% |
| Lasa Supergenerics Limited | -217.3 Million INR | 2037.184% |
| Sun Pharma Advanced Research Company Limited | -3.87 Billion INR | 208.716% |